PROCEPT BIOROBOTICS CORP
PRCTNASDAQTrading Snapshot
- Day Range
- $18.04 – $18.42
- 52-Week Range
- $16.67 – $38.11
- Volume
- $5.48B
- Avg Volume
- $4.75B
- Shares Outstanding
- 56.9M
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $308M
- Last Q Revenue
- $94M
- P/E Ratio
- —
- P/S Ratio
- 2.9x
- EPS (TTM)
- $-1.95
- Dividend Yield
- —
- Dilution (1yr)
- +4.1%
Why Investors Own PRCT
- ✓High-growth profile — revenue up +55.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PROCEPT BIOROBOTICS CORP
PRCT
StockOtter · stockotter.spaceAbout PROCEPT BIOROBOTICS CORP
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
PROCEPT BioRobotics (NASDAQ:PRCT) & Varex Imaging (NASDAQ:VREX) Critical Analysis
Varex Imaging (NASDAQ: VREX - Get Free Report) and PROCEPT BioRobotics (NASDAQ: PRCT - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies bas
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines – PRCT
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advi
Kaplan Fox Encourages PROCEPT BioRobotics Corporation (PRCT) Investors to Take Immediate Action in the Securities Class Action Before September 22, 2026
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: P
Portnoy Law Firm Announces Class Action on Behalf of PROCEPT BioRobotics Corporation Investors
LOS ANGELES, Sept. 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PROCEPT BioRobotics Corporation, (“PROCEPT” or the "Company") (NASDAQ: PRCT) investors of a class action on behalf of investors that bought sec
PROCEPT BioRobotics Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRCT
NEW YORK, Sept. 22, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or "the Company") (NASDAQ: PRCT ) violations of §§10(b) and 20(a)
Kaplan Fox Alerts PROCEPT BioRobotics Corporation (PRCT) Investors With Losses to a Securities Class Action - Act Before the September 22, 2026 Deadline
New York, New York--(Newsfile Corp. - September 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: P